Biomarker and companion diagnostic programmes are becoming more complex, more global and increasingly dependent on sophisticated data analysis. For drug developers, the challenge is not simply generating more data, but producing high-quality, actionable insights quickly enough to support clinical development decisions.
In a recent Oxford Global thought leadership interview, Patrick Reese, Vice President of Operations at CellCarta US, discussed how CellCarta is responding to these challenges through digital pathology, artificial intelligence and more flexible approaches to companion diagnostic development.
Moving Biomarker Programmes Faster
According to Reese, one of the most consistent messages from pharmaceutical and biotechnology companies is the need to accelerate biomarker programmes.
At the same time, sponsors are increasingly looking to incorporate artificial intelligence into clinical development while preparing programmes for global deployment and eventual commercialisation.
CellCarta has responded by building a digital pathology and AI consortium with a range of image analysis and artificial intelligence companies. Rather than relying on a single technology platform, the model enables CellCarta to bring different AI tools into its own framework and validate them to the standards required for clinical trials.
The objective is to give sponsors greater flexibility while helping move promising technologies from research applications towards clinical and regulatory use.
AI-Enabled Digital Pathology
Digital pathology is becoming particularly important as researchers seek to extract significantly more information from limited tissue samples.
CellCarta combines AI-enabled image analysis with its in-house pathology expertise across technologies including immunohistochemistry and immunofluorescence.
Reese explained that increasingly complex multiplex assays can generate large volumes of information from a single tissue section. AI can help accelerate the analysis of these datasets while supporting more consistent and comprehensive interpretation.
The result is the ability to provide researchers with richer biomarker datasets without requiring additional patient material.
A More Flexible Route to Companion Diagnostics
CellCarta is also developing what it describes as a CDx Accelerator Model.
The approach is designed to give drug developers an alternative starting point to a traditional companion diagnostic programme. Companies can begin with a centralised testing model during earlier clinical development, generating evidence and reaching key decision points before committing to a fully scaled CDx pathway.
As programmes progress, testing can then expand through regional and global laboratory networks and transition towards decentralised deployment following regulatory approval.
For Reese, the advantage is speed and optionality.
Earlier data can allow sponsors to make faster decisions, refine programmes and determine whether a biomarker strategy should continue towards full companion diagnostic development.
Supporting Global Clinical Development
Another challenge is the increasingly international nature of biomarker programmes.
Clinical studies may begin within a small number of sites before expanding rapidly across multiple countries and regions. CellCarta's global laboratory network allows programmes to move from exploratory biomarker research through clinical development and ultimately towards companion diagnostic deployment within a connected infrastructure.
The broader objective is to reduce fragmentation between discovery, clinical validation and commercial implementation.
As precision medicine continues to evolve, the combination of AI-enabled pathology, scalable laboratory networks and more adaptable CDx development models could help pharmaceutical and biotechnology companies reach critical development decisions earlier — and ultimately bring the right therapies to the right patients faster.







